WHO ICTRP trial
Regorafenib-pembrolizumab vs. TACE/TARE in intermediatestage HCC beyond up-to-7…
KCT0009093 · Clinical Research Information Service (CRIS) · Recruiting
Key facts
| Trial ID | KCT0009093 |
|---|---|
| Public title | Regorafenib-pembrolizumab vs. TACE/TARE in intermediatestage HCC beyond up-to-7 (REPLACE) |
| Scientific title | A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of… |
| Primary sponsor | Inje University Haeundae Paik Hospital |
| Registry | Clinical Research Information Service (CRIS) |
| Recruitment status | Recruiting |
| Study type | Interventional Study |
| Phase | Phase3 |
| Countries | Korea, Republic of |
| Conditions | Diseases of the digestive system |
| Interventions | Drug : * Investigational arm(Regorafenib+Pembrolizumab) 1. Regorafenib: -90 mg (3 x 30 mg tablets) orally -q.d for 3 weeks of a 4-week cycle (i.e., 3 weeks on, 1 week off). The regorafenib break must not be shorter than 7 days and should… |
| Registration date | Jan 5, 2024 |
| Target size | 496 |
| Registry page | cris.nih.go.kr |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: